论文部分内容阅读
葛兰素威康公司的皮质类固醇产品氟替卡松丙酸酯吸入剂 (ｆｌｕｔｉｃａｓｏｎｅｐｒｏｐｉｏｎａｔｅ ,Ｆｌｉｘｏｔｉｄｅ)已在德国获准用于治疗慢性阻塞性肺病 (ＣＯＰＤ)。这是类固醇吸入剂首次获准用于该适应证。该公司与ＡｓｔｒａＺｅｎｅｃａ公司希望打进潜在的巨大Ｃ?
Glaxo Wellcome’s corticosteroid fluticasone propionate (flixotide) has been approved for the treatment of chronic obstructive pulmonary disease (COPD) in Germany. This is the first time a steroid inhaler has been approved for this indication. The company and AstraZeneca want to tap into potentially huge C?